Bayer's Legal Overhang and Cautious Analyst Stance Cloud a Busy Pipeline Week

JPMorgan keeps Overweight and EUR 61 target on Bayer ahead of its 3 November Q3 statement, flagging optimism on agriculture timing.

Bayer heads into its third-quarter report with a familiar split-screen problem: scientific and commercial progress on one side, a swelling US litigation docket on the other. JPMorgan's Richard Vosser kept his "Overweight" rating and a EUR 61 price target on the stock, but cautioned that early market expectations for the quarter look too optimistic — pointing in particular to timing effects in the agricultural division. The note, issued midweek, landed as the shares were already losing ground.

By Friday's close, Bayer settled at EUR 45.02, a 10% decline across the week. The pullback dents a still-solid year-to-date gain of 22%, suggesting investors are trimming exposure ahead of the November update rather than abandoning the position outright.

Two Regulators, One Rare-Disease Designation

On the pipeline front, Bayer and its subsidiary BlueRock Therapeutics picked up a regulatory win when both the US Food and Drug Administration and the European Medicines Agency granted orphan-drug status to the experimental cell therapy lemiretprocel (OpCT-001). The designation covers primary photoreceptor diseases and carries development incentives reserved for rare-disease treatments.

The company also widened its over-the-counter footprint, launching MiraSOFT — a stool softener built on docusate sodium — in the US on Tuesday. The product will be stocked across more than 7,000 CVS pharmacy locations.

mRNA Patent Case Clears an Early Hurdle

Bayer notched a partial legal victory as well. US federal judge William Bryson on 28 September rejected motions from Pfizer, BioNTech and Moderna seeking dismissal of a Bayer-Monsanto patent suit tied to mRNA technology. Reuters reported that the ruling does not yet establish any patent infringement by the vaccine makers, but it keeps the Leverkusen-based group's case alive.

That procedural win does little to offset the broader litigation burden. In Missouri, a trial got underway involving Roundup claims from three plaintiffs alleging faulty product design and inadequate testing. Roughly 65,000 Roundup cases are pending across US federal and state courts, according to Reuters. The Missouri proceeding sits outside the proposed collective settlement and is moving forward despite a US Supreme Court ruling on warning labels. Bayer rejects the allegations.

Ohio Plant, Hybrid Bonds and a Portfolio Prune

Operationally, Bayer continues to build out capacity and reshape its balance sheet. The group plans a pharmaceutical production site in New Albany, Ohio, carrying a USD 2.2 billion investment and roughly 600 jobs, with the first production module targeted to come online in 2031.

Alongside that, Bayer placed EUR 2 billion in hybrid bonds and agreed to sell the cancer drug Stivarga to Grünenthal for up to EUR 375 million. Dr. Christoph Koenen has stepped into the Chief Medical Officer role for the pharmaceutical division.

November 3 Sets the Record Straight

The decisive test comes on 3 November 2026, when Bayer publishes its quarterly statement for the third quarter. Only then will investors learn how deeply the agricultural unit is being squeezed — and whether JPMorgan's restrained tone was the right call.